were patients who had the procedure performed electively for stable or unstable angina pectoris or after several days of stabilization after acute myocardial infarction. Those who had the procedure performed acutely in the setting of a myocardial infarction or after cardiopulmonary resuscitation for cardiac arrest were excluded. Of the total, 7,221 patients had successful dilatation of all lesions attempted without in-hospital complications of death, myocardial infarction, or coronary surgery. All patients who underwent an angiographic restudy at Emory University or Crawford W. Long Hospitals were identified. A total of 3,363 patients (47%) fulfilled the following criteria: 1) an angiographically successful angioplasty; 2) no hospital complications of death, Q-wave myocardial infarction, or coronary bypass surgery; and 3) angiographic restudy 4-12 months after angioplasty or earlier if restenosis occurred. These 3,363 patients form the basis of this study. These patients returned for restudy after angioplasty because of symptoms or signs of ischemia or to determine whether restenosis had occurred. These patients were also compared with the 3,858 who did not return for restudy.
Definitions
Single-vessel disease: 250% diameter luminal narrowing in either the left anterior descending, left circumflex, or right coronary artery or a major branch or branches.
Multiple-vessel disease: the presence of .50% diameter luminal narrowing in more than one of these major epicardial vessel systems.
Angiographically successful angioplasty: all lesions attempted improved >20% in diameter stenosis and were dilated to <50% residual diameter stenosis.
Restenosis: recurrent diameter narrowing of >50% of any site dilated within 1 year of the original angioplasty.
Variables defined by patient history: hypertension, diabetes, severity of angina, prior myocardial infarction, myocardial infarction during follow-up.
Data Collection
Baseline and restudy demographic, clinical, angiographic, and procedural data including complications were recorded prospectively by physicians on standardized forms and entered into a computerized data base. Table 1 . The mean age of each group was the mid 50s, with restenosis patients slightly older. No difference was noted in sex. Hypertension was more common in the restenosis population. Diabetes was more common in the restenosis group (14.0%) than in the group without restenosis (9.8%), and 55.7% of diabetics suffered restenosis compared with 45.5% of nondiabetics. No difference in cigarette smoking was noted between groups. About 30% of each group had had a prior myocardial infarction. Severe angina at the time of the index angioplasty was more common in patients with subsequent restenosis (60.6%) than in those without restenosis (50.7%), and 51.7% of patients with Canadian Cardiovascular Society angina grade III-IV suffered restenosis compared with 41.7% of patients with angina grade 0-II. Angiographic characteristics are compared in Table 2 . Most ejection fractions were normal and were not noted to be different between groups. Multivessel disease and multisite angioplasty were more common in the restenosis group. Patients with single-vessel disease had a 44.7% restenosis rate compared with 52.4% in multiple-vessel disease. Singlesite angioplasty patients had a 44.1% restenosis rate compared with 57.5% in multiple-site angioplasty. The diameter stenosis refers to the dilatation site most severely obstructed on the restudy angiogram. The severity of the occlusion both before and after angioplasty was greater in the restenosis group.
Characteristics at the time of the restudy angiogram are compared in Table 3 . The time to angiographic restudy was longer in the group without restenosis. By definition, the stenosis was much more severe in the restenosis group. Angina at restudy was assessed by history taken before the angiogram. In the group with restenosis, 70.7% had angina versus 38.7% in the group without restenosis. Follow-up an average of just over 3 years after the angioplasty showed no difference in the prevalence of angina between groups, with just over 30% still having angina.
Six-year survival is displayed in Figure 1 for each group. Mortality during the first year after angioplasty was very low in both groups, such that survival in both groups was 0.99 at 1 year. The group without restenosis has a 6-year survival of 0.95, and the group with restenosis has a 6-year survival of 0.93 (p=0.16). The multivariate correlates of late death (Table 4) were older age, diabetes, increased number of vessels diseased, and a trend for prior myocardial infarction. Female sex was a univariate correlate. Myocardial infarctions were more common in the group with reste- difference after angioplasty. For most variables, the values in the group not restudied were between those with and without restenosis in the restudy group. Follow-up data are compared in the two groups in Table 8 .
Although survival was higher in the restudy group, note that only 1.1% of the group without restudy died by 6 months. In contrast, freedom from myocardial infarction was higher in the group without restudy at 6 Discussion In this article, we have presented detailed information on the prognosis after successful angioplasty in patients who are shown either to have or not to have restenosis within 1 year. The two populations differed by several variables that are frequently noted to be risk factors for restenosis, and at the time of restudy, more of the patients with restenosis reported severe angina. Recurrent angina is likely to prompt angiographic restudy, suggesting that the difference in angina may be even greater than shown here. Although follow-up data reveal that survival was excellent in both groups and that restenosis was not shown to be a multivariate correlate of death, myocardial infarctions were more common with restenosis. This difference was noted entirely in the first 6 months after the original procedure when the restenosis process was occurring. A major difference between the groups was the more frequent need for additional revascularization procedures in the patients with restenosis. The highest event rates were noted in the patients with restenosis who presented with angina. These data are set within the context of all patients having a first successful revascularization procedure by angioplasty during this period. The baseline clinical, angiographic, and procedural characteristics differed somewhat in the patients with and without angiographic restudy. As might be expected, there were many more repeat revascularization procedures in the group undergoing angiographic restudy. The mortality was actually higher in the patients not undergoing restudy. At 6 months, the mortality in the nonrestudy patients was 1.1%, and many of these deaths may have been in patients with restenosis who never came to angiographic restudy.
The high survival rates noted in this study are consistent with several previously published reports.17-20 Similar nonfatal event rates have previously been noted in an early series from Emory,18 including the high inci- dence of additional revascularization procedures. Additional revascularization in the group without restenosis has been shown to be higher in patients with disease elsewhere in their coronary arteries, even if it was thought initially to be nonobstructive at the time of the angiographic restudy.21 Repeat angioplasty of restenotic lesions has a high success rate, with strikingly low morbidity and mortality.5-10 However, the risk of a second episode of restenosis is relatively high.5'9'10 Perhaps the most striking aspect of these data is the small difference in survival between the groups with and without restenosis despite an older age distribution, more diabetes, more severe angina, more multivessel disease, and more repeat revascularization procedures in the restenosis group. Restenosis was not a multivariate correlate of late death. Although there were more deaths in the group not undergoing restudy, the difference between groups was small, and even if most of these deaths were in patients with restenosis, the mortality in all patients with restenosis is likely to be only 1-2% higher than that noted in the patients with restenosis who were restudied. Although the myocardial infarction rate was different between the groups and the difference is certainly of clinical importance, the overwhelming majority of the patients with restenosis did not suffer a myocardial infarction. The data on myocardial infarctions must be viewed as somewhat soft, because the diagnosis of a myocardial infarction after discharge was based on patient-provided information. In addition, patients with recurrent chest pain or patients who are told that they have restenosis or probable restenosis may be more likely to say that they have had a "heart attack."22 A recent study from Emory reviewed results of repeat procedures in patients with restenosis.5 This study included 1,460 patients with restenosis who also formed part of the population for the present study. Of these 1,460, 1,051 (70%) had repeat angioplasty, with 0.8% Q-wave myocardial infarctions and 0.1% death. Coronary surgery was performed as a primary form of therapy after restenosis in 76 patients (5.1%). There were 3.3% Q-wave myocardial infarctions and no deaths. Thus, we can ascribe very few deaths or myocardial infarctions to procedures. The frequent revascularization procedures in the patients with restenosis make it impossible to determine what the survival and freedom from myocardial infarction would have been without these procedures. It is possible that the incidence of myocardial infarction in the restenosis group would have been much higher without additional revascularization. The difference in revascularization rate, of course, cannot be said to reflect any biological significance, since it is the restenotic lesions that lead to the patients' undergoing repeat revascularization. The highest rate of events was in the symptomatic patients with restenosis. This suggests that the practice of using chest pain as a guide to restudy may be appropriate. Although noninvasive testing may be a reasonable adjunct to symptomatic status, this cannot be ascertained from these data.
Implications for Restenosis Trials
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